Research Article

Detection of Epithelial-Mesenchymal Transition Status of Circulating Tumor Cells in Patients with Esophageal Squamous Carcinoma

Dingpei Han, Kai Chen, Jiaming Che, Junbiao Hang, and Hecheng Li

Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China

Correspondence should be addressed to Junbiao Hang; hang jb@163.com and Hecheng Li; lihecheng2000@hotmail.com

Received 27 February 2018; Accepted 29 May 2018; Published 26 June 2018

Academic Editor: Christian Schwentner

Copyright © 2018 Dingpei Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To investigate the correlation between the status of epithelial-mesenchymal transition (EMT) of circulating tumor cells (CTCs) and esophageal squamous cell carcinoma (ESCC).

Methods. The demographic data and blood samples of 21 patients with ESCC were collected retrospectively. CTCs were enriched by using optimized CanPatrol TM CTC enrichment technique. CTCs were identified and characterized according to the EMT markers (e-CTCs: epithelial CTCs; mix-CTCs: epithelial-mesenchymal-mixed CTCs; m-CTCs: mesenchymal CTCs). The correlation between CTCs and demographic data was analyzed.

Results. Total 129 CTCs were detected in all the patients: 11(8.5%) CTCs of them were e-CTCs, 76(58.9%) were mix-CTCs, and 42(32.6%) were m-CTCs. The average number of CTCs from each patient was 6.1±7.1 which included 0.5±0.9 of e-CTCs, 3.6±5.2 of mix-CTCs, and 2.0±2.7 of m-CTCs; the difference between the three groups was significant (P = 0.017): the number of total CTCs was correlated with the number of mix-CTCs (R2=0.883, P<0.01) and m-CTCs (R2=0.639, P<0.01) but not e-CTCs (R2=0.012, P = 0.641) and the number of CTCs was correlated with the N stage and TNM stage in this study (R2=0.698 and R2=0.359).

Conclusions. Mix-CTCs and m-CTCs might play an important role in progression of ESCC; the number of CTCs in ESCC might have the potential to be a predictor of prognosis.

1. Introduction

Esophageal cancer ranks 5th in morbidity and 4th in mortality of all diagnosed cancers in China. Patients suffer great pain and undergo low quality of life after complex but so far most effective esophagectomy. In Asian, esophageal squamous cell carcinoma (ESCC) accounts for over 90% of all cases of esophageal cancer [1]; the poor prognosis is largely due to the rapid progress of local recurrences and metastasis. However, there are no specific tumor markers for early and small recurrences. In recent studies, the circulating tumor cells (CTCs) have been used as a “window” to monitor tumor prognosis [2]. In a case report, the CTCs counts in blood sample from a patient with esophageal cancer were in accordance with imaging scans at several time points [3]. With the advantage of accessible sampling, CTCs can investigate tumor progression in real time and monitor the response to further treatment [4].

Recurrence and metastasis are associated with multiple steps such as invasion, migration, and proliferation [5]. The epithelial-mesenchymal transition (EMT) in cancer metastasis is known to be regulated by several proteins that play important roles in invasion and migration of tumor cells [6]. During the process of EMT, the epithelial tumor cells lose their polarity which result in invasion into the surrounding tissues and penetration through vessel walls [7]. It is possible to detect the EMT status of CTCs in blood sample, just as what had been reported that aberrant activation of EMT was involved in the dissemination of tumor cells [8].

As we all know, during the EMT process of tumor cells, the expression of epithelial cell adhesion molecule (EpCAM) and cytokeratins (CK) will be downregulated, while the expression of twist and vimentin will be upregulated [9]. The EpCAM and CK are epithelial genes, and the vimentin and twist are mesenchymal genes. The mentioned genes are the common biomarkers of EMT and currently used
as biomarkers of CTCs [10]. However, the EpCAM-based enrichment technique which is one of the most commonly used methods to isolating CTCs has limitation for detection of the subgroup of CTCs with accomplished EMT [11]. In recent years, a quantifiable dual-colorimetric RNA in situ hybridization assay was proposed and adopted in the research focused on EMT of CTCs in breast cancer [12]; there was no report on isolation of CTCs from patients with ESCC by this method. In this study, we firstly applied this enrichment technique (optimized CanPatrolTM CTC enrichment [13]) to isolate CTCs from blood samples of patients with ESCC, with the purpose of demonstrating the relationship between the EMT status of CTCs and ESCC.

2. Materials and Methods

2.1. Patients and Blood Samples. 21 patients were recruited from January 2014 to June 2014 in Ruijin Hospital, Shanghai Jiaotong University School of Medicine. All the patients were diagnosed with ESCC by preoperative endoscopic biopsy and underwent esophagectomy with 2-field lymphadenectomy. The demographic data were shown in Table 1. We excluded the cases with the following criteria: patients with unresectable tumors, patients with preoperative chemotherapy or radiotherapy, and patients with ASA IV and V state. Blood samples of the 21 patients were collected at 1 day before surgery. We used the sample collection kit (Surexam, Guangzhou, China); the process of blood samples was as follows: 5ml blood was collected in tubes with EDTA; after being shaken, the blood samples were transferred into the preservative tubes with ammonium chloride-based lysing buffer and then incubated for 30 minutes at room temperature.

2.2. CTC Enrichment. After being centrifuged, the blood samples in tubes were stratified. The top supernatant layer was discarded, and 5 ml PBS (Sigma, St. Louis, USA) was added to the remain cell suspensions. A filtration tube (Surexam, Guangzhou, China) with 8-micrometer-pore membrane filter (Millipore, Billerica, USA) was used. When the cell suspensions flew through the filter, the much larger CTCs were retained on the filter, while the other cells passed through. At last, the CTCs were fixed by 2% formaldehyde on the filters. A vacuum plate with valve settings (Surexam, Guangzhou, China) was applied in the filtration.

2.3. RNA In Situ Hybridization (ISH) Assay. The RNA-ISH method in this study was based on the branched DNA (bDNA) signal amplification technology [14]. The process of the RNA-ISH in this study was briefly as follows [13]: a 24-well plate (Corning, NY, USA) was used to treat the cells treated with a protease, then the hybridization was performed at 42°C for 2 hours, and the probes specific for the epithelial (EpCAM and CK8/18/19), mesenchymal (Vimentin and twist) and leukocyte (CD45) biomarker are shown in Table 1. After the unbound probes were washed out, the signal amplifications were performed at 42°C for 20 minutes with a cocktail preamplifier solution. Finally, the membranes were incubated with amplifier solution at 42°C for 20 minutes; then, the cells were stained by DAPI (Sigma, St. Louis, USA) for 5 minutes. The assay was analyzed by a fluorescence microscope (100x oil objective, Olympus BX53, Tokyo, Japan). The red dots of signal represented the epithelial biomarker expression, the green ones represented the mesenchymal biomarker expression, and the blue ones represented the leukocytes.

2.4. Statistical Analyses. The SPSS software program (Statistical Package for Social Sciences, vision 11.0) was used for statistical analysis. The measurement data were presented as mean ± SD and analyzed by the one-way ANOVA. The correlation

| Biomarker | Sequences (5’-3’) |
|-----------|------------------|
| CD45      | TCGCAATTCCTATGCAGACTC |
| EpCAM     | TGGTGCTGTTGATGTAATG |
| CK8       | GACGGGCTTTGGACAGAGC |
| CK18      | CTGGATGAAAGGAGACAGG |
| Vimentin  | GAGCGAGAGTGGCCGAGAG |
| Twist     | AAGATGGACCTGAGAGAG |

Table 1: Capture probe sequences for the biomarkers.
Table 2: Demographic data.

| Variables          | N (%)/mean±SD |
|--------------------|---------------|
| Gender             |               |
| male               | 17(80.9)      |
| female             | 4(19.1)       |
| Age                | 59.5 ± 8.2    |
| BMI                | 23.2 ± 3.5    |
| Tumor Location     |               |
| Middle             | 16(76.2)      |
| lower              | 5(23.8)       |
| Pathology          |               |
| Squamous           | 21(100)       |
| Others             | 0(0)          |
| Differentiation    |               |
| I                  | 2(9.5)        |
| I-II               | 1(4.8)        |
| II                 | 9(42.8)       |
| II-III             | 6(28.6)       |
| III                | 3(14.3)       |
| pT Stage*          |               |
| 1                  | 3(14.3)       |
| 2                  | 4(19.0)       |
| 3                  | 14(66.7)      |
| pN Stage*          |               |
| 0                  | 6(28.6)       |
| 1                  | 8(38.1)       |
| 2                  | 4(19.0)       |
| 3                  | 3(14.3)       |
| pTNM Stage*        |               |
| I                  | 3(14.3)       |
| II                 | 3(14.3)       |
| III                | 12(57.1)      |
| IV                 | 3(14.3)       |

*8th AJCC TNM staging.

Analysis was analyzed by Pearson correlation coefficient. P < 0.05 is considered to be statistically significant.

3. Results and Discussion

3.1. Results. The demographic data of all the 21 patients are shown in Table 2. The mean size of tumors in this study was 16.9±26.0 cm³; the mean length of specimens was 8.0±1.9 cm.

As shown in Figure 1, three types of CTCs were detected in this study: epithelial CTCs (e-CTCs), epithelial-mesenchymal-mixed CTCs (mix-CTCs), and mesenchymal CTCs (m-CTCs). Total 129 CTCs were detected in all the patients, 11(8.5%) CTCs of them were e-CTCs, 76(58.9%) were mix-CTCs, and 42(32.6%) were m-CTCs. The average number of CTCs from each patient was 6.1 ± 7.1 which included 0.5 ± 0.9 of e-CTCs, 3.6 ± 5.2 of mix-CTCs, and 2.0±2.7 of m-CTCs; the difference between the three groups was significant (P = 0.017, Figure 2). In addition, as shown in Figure 3, the number of CTCs was correlated with the number of mix-CTCs (R² = 0.883, P < 0.01, Figure 3(b)) and m-CTCs (R² = 0.639, P < 0.01, Figure 3(c)) but not e-CTCs (R² = 0.012, P = 0.641, Figure 3(a)).

As shown in Table 3, the results of correlation analysis showed that the number of CTCs was correlated with the number of mix-CTCs (R² = 0.698 and R² = 0.359, respectively).

Table 3: Correlation between total CTCs and demographic data.

| Variables          | R²    | P value |
|--------------------|-------|---------|
| Gender             | 0.040 | 0.385   |
| Age                | 0.009 | 0.687   |
| BMI                | 0.013 | 0.627   |
| Tumor location     | 0.049 | 0.336   |
| Tumor size         | 0.026 | 0.487   |
| T stage*           | 0.151 | 0.082   |
| N stage*           | 0.698 | <0.01   |
| TNM stage*         | 0.359 | 0.004   |
| Differentiation    | 0.029 | 0.459   |

*8th AJCC TNM staging.
4. Discussion

Valuable biomarkers for detection of the tumor progression and treatment outcome are important in clinical cancer research [15], especially in ESCC which is accompanied by poor prognosis due to high incidences of metastasis. In clinical practice, we used computed tomography and serum tumor markers to investigate the progression of tumor in most cases, but these methods frequently lack sensitivity and specificity. In recent years, the function of CTCs in the tumor progression has been a research hotspot although the concept of CTCs was first recognized over 50 years ago [16]. With the development of molecular biological technique, many approaches have been developed to enrich CTCs in blood samples. The most widely used approach is CellSearch™ System [17], which has been applied in many types of cancer like breast, colorectal, and prostate cancer [18, 19]. However, the CellSearch™ System can only detect e-CTCs; it was reported that e-CTCs comprised just a small part (4.5%) of all CTCs in patients with hepatocellular [20]. The similar result was demonstrated in this study; only 8.5% of all CTCs were e-CTCs in ESCC. As the EMT is involved in the dissemination of tumor cells [8], we think that the conclusions from CellSearch™ System might have some limitations in the field of tumor progression; the similar result was reported in other study [21].

According to this study, in all the 129 CTCs from 21 patients with ESCC, 76 (58.9%) were mix-CTCs and 42 (32.6%) were m-CTCs, and the correlation analysis suggested that the number of CTCs was correlated with the number of mix-CTCs and m-CTCs. The results indicated that most CTCs from esophageal cancer had underwent EMT. It also suggested that EMT might play an important role in metastasis of ESCC, although the conclusion needs to be verified by study with more samples.

The ability to detect the CTCs at any stage of tumor provides a good method to diagnosis, monitoring, and prognostic evaluation [22, 23]. In this study, we detected the presence of CTCs in patients with T1 or N0 tumor, suggesting that EMT could occur in early stage of ESCC. This might be a reason for the high incidences of metastasis of ESCC, and it corresponded the fact that lymphatic metastasis could happen in T1 cases due to the abundant lymphatic network at submucosa.

The small sample size was a limitation of this study, and it might also cause bias in the statistical result. However, we found mix-CTCs of m-CTCs might be a predictor of prognosis for ESCC in this study; the result was evidenced by other publications that CTCs could predict the survival in ESCC [24], esophageal adenocarcinoma [25], and other malignancy such as prostate cancer [26]. Whether the different types of CTCs enriched by the method of this study would be a better
predictor of prognosis for ESCC should be investigated by studies with more samples.

5. Conclusions

We found that the number of CTCs was correlated with ESCC progression although the sample size in this study was small. Mix-CTCs and m-CTCs might play an important role in EMT of ESCC, and the number of these CTCs in ESCC might have the potential to be a predictor of prognosis. The mechanism of promotion of EMT in CTCs from ESCC should be elucidated in further studies.

Data Availability

The date used to support the findings of this study are limitedly available from the first author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This study was supported by the grant from Science and Technology Commission of Shanghai Municipality Medical Guidance Science & Technology Support Project [16411966100], Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20172005], and Shanghai Municipal Commission of Health and Family Planning Outstanding Academic Leaders’ Training Program [2017BR055]. The authors are grateful to Dr. Xiang Zhou and Dr. Xiaoqing Yang for their valuable support; they are all from Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China.

References

[1] F. Kamangar, G. M. Dore, and W. F. Anderson, “Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137–2150, 2006.
[2] T. W. Friedlander, V. T. Ngo, H. Dong et al., “Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer,” International Journal of Cancer, vol. 134, no. 10, pp. 2284–2293, 2014.
[3] Y.-Y. Qiao, K.-X. Lin, Z. Zhang et al., “Monitoring disease progression and treatment efficacy with circulating tumor cells in esophageal squamous cell carcinoma: A case report,” World Journal of Gastroenterology, vol. 21, no. 25, pp. 7921–7928, 2015.
[4] N. Bednarz-Knoll, C. Alix-Panabières, and K. Pantel, “Clinical relevance and biology of circulating tumor cells,” Breast Cancer Research, vol. 13, no. 6, article 228, 2011.
[5] P. S. Steeg, “Tumor metastasis: Mechanistic insights and clinical challenges,” Nature Medicine, vol. 12, no. 8, pp. 895–904, 2006.
[6] B. D. Craene and G. Berx, “Regulatory networks defining EMT during cancer initiation and progression,” Nature Reviews Cancer, vol. 13, no. 2, pp. 97–110, 2013.
[7] M. Guarino, “Epithelial-mesenchymal transition and tumour invasion,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 12, pp. 2153–2160, 2007.
[8] J. P. Their, “Epithelial-mesenchymal transitions in tumor progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002.
[9] R. Kalluri, “EMT: when epithelial cells decide to become mesenchymal-like cells,” The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1417–1419, 2009.
[10] M. Giuliano, A. Giordano, S. Jackson et al., “Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment,” Breast Cancer Research, vol. 13, no. 3, article no. R67, 2011.
[11] T. M. Gorges, I. Tinhofer, M. Drosh et al., “Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition,” BMC Cancer, vol. 12, article 178, 2012.
[12] M. Yu, A. Bardia, B. S. Wittner et al., “Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition,” Science, vol. 339, no. 6119, pp. 580–584, 2013.
[13] S. Wu, S. Liu, Z. Liu et al., “Classification of circulating tumor cells by epithelial-mesenchymal transition markers,” PLoS ONE, vol. 10, no. 4, Article ID e0123976, 2015.
[14] G. J. Tsongalis, “Branched DNA technology in molecular diagnostics,” American Journal of Clinical Pathology, vol. 126, no. 3, pp. 448–453, 2006.
[15] D. G. de Castro, P. A. Clarke, B. Al-Lazikani, and P. Workman, “Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance,” Clinical Pharmacology & Therapeutics, vol. 93, no. 3, pp. 252–259, 2013.
[16] R. F. Alexander and A. I. Spriggs, “The differential diagnosis of tumour cells in circulating blood,” Journal of Clinical Pathology, vol. 13, no. 5, pp. 414–424, 1960.
[17] M. Cristofanilli, G. T. Budd, M. J. Ellis et al., “Circulating tumor cells, disease progression, and survival in metastatic breast cancer,” The New England Journal of Medicine, vol. 351, no. 8, pp. 781–791, 2004.
[18] E. Andreopoulou, L.-Y. Yang, K. M. Rangel et al., “Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system,” International Journal of Cancer, vol. 130, no. 7, pp. 1590–1597, 2012.
[19] M. C. Miller, G. V. Doyle, and L. W. Terstappen, “Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer,” Journal of Oncology, vol. 2010, Article ID 617421, 8 pages, 2010.
[20] Y.-K. Liu, B.-S. Hu, Z.-L. Li, X. He, Y. Li, and L.-G. Lu, “An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients,” Hepatology International, vol. 10, no. 4, pp. 640–646, 2016.
[21] H. Li, P. Song, B. Zou et al., “Circulating tumor cell analyses in patients with esophageal squamous cell carcinoma using epithelial marker-dependent and -independent approaches,” Medicine (United States), vol. 94, no. 38, Article ID e5655, 2015.
[22] M. G. Krebs, R. L. Metcalf, L. Carter, G. Brady, F. H. Blackhall, and C. Dive, “Molecular analysis of circulating tumour cells—biology and biomarkers,” Nature Reviews Clinical Oncology, vol. 11, no. 3, pp. 129–144, 2014.
[23] S. Maheswaran, L. V. Sequist, S. Nagraj et al., “Detection of mutations in EGFR in circulating lung-cancer cells,” The New England Journal of Medicine, vol. 359, no. 4, pp. 366–377, 2008.
[24] X.-D. Yin, X. Yuan, J.-J. Xue, R. Wang, Z.-R. Zhang, and J.-D. Tong, “Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy,” Diseases of the Esophagus, vol. 25, no. 8, pp. 750–756, 2012.

[25] F. Sclafani, E. Smyth, D. Cunningham, I. Chau, A. Turner, and D. Watkins, “A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers,” Clinical Colorectal Cancer, vol. 13, no. 2, pp. 94–99, 2014.

[26] J. S. de Bono, H. I. Scher, R. B. Montgomery et al., “Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 14, no. 19, pp. 6302–6309, 2008.